ENG/中
老虎證券
市场
行情
24/7新闻
产品
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
AgomAb Therapeutics
5.45
-0.1700
-3.02%
盤後:
5.45
0.0000
0.00%
17:00 EST
成交量:
18.89萬
成交額:
105.82萬
市值:
2.68億
市盈率:
-1.21
高:
5.78
開:
5.57
低:
5.39
收:
5.62
52周最高:
17.82
52周最低:
5.39
股本:
4,924.80萬
流通股本:
2,605.96萬
量比:
0.83
換手率:
0.73%
股息:
- -
股息率:
- -
每股收益(TTM):
-4.5143
每股收益(LYR):
-168.1598
淨資產收益率:
-39.22%
總資產收益率:
-20.58%
市淨率:
2.65
市盈率(LYR):
-0.03
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Agomab宣佈Ontunisertib治療纖維狹窄性克羅恩病全球Nov-Era 2B期研究首例患者給藥
美股速递
·
10/14
AgomAb Therapeutics影像學評估顯示纖維化狹窄在治療期間呈穩定趨勢
美股速递
·
10/01
Agomab Therapeutics:Ontunisertib治療FSCD滿60周,安全性與耐受性持續良好
美股速递
·
10/01
Agomab Therapeutics:AGMB-447在IPF患者中展示出4.5毫克Bid劑量下的優越安全性與耐受性
美股速递
·
09/15
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/AGMB"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":5.45,"timestamp":1795208400000,"preClose":5.62,"halted":0,"volume":188938,"hourTrading":{"tag":"盘后","latestPrice":5.45,"preClose":5.45,"latestTime":"17:00 EST","volume":9309,"amount":50615.43,"timestamp":1795212057537,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.030249110320284683,"floatShares":26059600,"shares":49248000,"eps":-4.51426,"marketStatus":"休市中","change":-0.17,"latestTime":"11-20 16:00:00 EST","open":5.57,"high":5.78,"low":5.39,"amount":1058180.616557,"amplitude":0.069395,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":5.62,"postHourTrading":{"tag":"盘后","latestPrice":5.45,"preClose":5.45,"latestTime":"17:00 EST","volume":9309,"amount":50615.43,"timestamp":1795212057537,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8291524975693485},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":26059600,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.8291524975693485,"shares":49248000,"dividePrice":0,"high":5.78,"amplitude":0.069395,"preClose":5.62,"low":5.39,"week52Low":5.39,"pbRate":"2.65","week52High":17.82,"institutionHeld":0,"latestPrice":5.45,"eps":-4.51426,"divideRate":0,"volume":188938,"delay":0,"ttmEps":-4.51426,"open":5.57,"prevYearClose":16,"prevWeekClose":6.36,"prevMonthClose":7.49,"prevQuarterClose":11.1,"fiveDayClose":6.36,"twentyDayClose":9.05,"sixtyDayClose":13.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787720400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-11-20","current":-1.207285,"percent":1,"low":-14.725744,"twenty":-10.03314,"median":-8.390444,"eighty":-6.758814,"high":-3.783472,"avg":-8.648615,"sd":2.593596,"marketCap":276773619},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-10-02","current":-5.676951,"twenty":-11.106435,"median":-8.772569,"eighty":-7.554749,"marketCap":425994983},{"date":"2026-10-09","current":-6.083739,"twenty":-10.939059,"median":-8.723327,"eighty":-7.469186,"marketCap":454066329},{"date":"2026-10-16","current":-5.438404,"twenty":-10.785376,"median":-8.700726,"eighty":-7.398113,"marketCap":407773233},{"date":"2026-10-23","current":-5.971566,"twenty":-10.689941,"median":-8.68439,"eighty":-7.245522,"marketCap":445694173},{"date":"2026-10-30","current":-4.956603,"twenty":-10.620842,"median":-8.637765,"eighty":-7.126432,"marketCap":368867332},{"date":"2026-11-06","current":-5.059893,"twenty":-10.317052,"median":-8.480538,"eighty":-7.011802,"marketCap":376008289},{"date":"2026-11-13","current":-4.249696,"twenty":-10.078189,"median":-8.451671,"eighty":-6.84303,"marketCap":313217121},{"date":"2026-11-20","current":-3.783472,"twenty":-10.03314,"median":-8.390444,"eighty":-6.758814,"marketCap":276773619}],"updateTime":1795368108721},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1145907308","title":"Agomab宣佈Ontunisertib治療纖維狹窄性克羅恩病全球Nov-Era 2B期研究首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1145907308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145907308?lang=zh_tw&edition=fundamental","pubTime":"2026-10-14 04:10","pubTimestamp":1791922259,"startTime":"0","endTime":"0","summary":"Agomab宣布Ontunisertib治疗纤维狭窄性克罗恩病全球Nov-Era 2B期研究首例患者给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117111798","title":"AgomAb Therapeutics影像學評估顯示纖維化狹窄在治療期間呈穩定趨勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1117111798","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117111798?lang=zh_tw&edition=fundamental","pubTime":"2026-10-01 18:31","pubTimestamp":1790850718,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics影像学评估显示纤维化狭窄在治疗期间呈稳定趋势","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112672519","title":"Agomab Therapeutics:Ontunisertib治療FSCD滿60周,安全性與耐受性持續良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1112672519","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112672519?lang=zh_tw&edition=fundamental","pubTime":"2026-10-01 18:31","pubTimestamp":1790850669,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics Nv 宣布,其药物 Ontunisertib 在治疗纤维性狭窄性克罗恩病(FSCD)的过程中,长达 60 周的疗程里始终维持了令人满意的安全性与耐受性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108737836","title":"Agomab Therapeutics:AGMB-447在IPF患者中展示出4.5毫克Bid劑量下的優越安全性與耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108737836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108737836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:13","pubTimestamp":1789416788,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics公司今日宣布,其候选药物AGMB-447在特发性肺纤维化(IPF)患者中展现出令人鼓舞的安全性和耐受性数据。该项研究聚焦于4.5毫克每日两次(Bid)的给药方案,初步结果令人振奋。\n数据表明,该剂量水平下的药物耐受性表现良好,患者未出现预期之外的不良事件。这一发现为AGMB-447的后续临床开发奠定了坚实基础。\n作为一家专注于纤维化疾病治疗领域的生物制药企业,Agomab Therapeutics正积极推进该候选药物的临床研究进程。此次公布的结果进一步验证了公司在纤维化治疗管线上的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGMB\",params:#limit:6,delay:false,,,undefined,":[]}}